10:57 AM EST, 12/20/2024 (MT Newswires) -- Fennec Pharmaceuticals ( FENC ) said licensing partner Norgine Pharmaceuticals received positive final draft guidance from the National Institute for Health and Care Excellence recommending Pedmarqsi for use in England and Wales to prevent cisplatin-induced hearing loss in patients aged 1 month to 17 years with localized, non-metastatic solid tumors.

"Securing access to Pedmarqsi is a critical milestone for the cancer community in England and Wales to help reduce the risk of ototoxicity, or permanent hearing loss, associated with cisplatin treatment," Fennec Chief Executive Officer Jeff Hackman said Friday in a statement.

Price: 5.89, Change: +0.05, Percent Change: +0.86